Biological response modifier therapy for refractory childhood uveitis.
about
Pars Planitis: Epidemiology, Clinical Characteristics, Management and Visual PrognosisThe Future Is Now: Biologics for Non-Infectious Pediatric Anterior UveitisDiagnosis and Management of Multiple Sclerosis in ChildrenHigh-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis.Review of Systemic Immunosuppression for Autoimmune UveitisResponse of pediatric uveitis to tumor necrosis factor-α inhibitors.Current evidence of anti-tumor necrosis factor α treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs.Disease-modifying therapy of pediatric multiple sclerosis.A role for tumor necrosis factor-alpha in experimental Bacillus cereus endophthalmitis pathogenesis.Uveitis Reactivation in Children Treated With Tumor Necrosis Factor Alpha Inhibitors.Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis.High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis.A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial).Clinical review: Anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience.Pharmacotherapy of uveitis.Antitumor necrosis factor treatment for pediatric inflammatory bowel disease.Road to remission: a comprehensive review of therapy in uveitis.Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis.Biological agents for the treatment of uveitis.The role of biologic agents in the management of non-infectious uveitis.Systemic treatment of vitreous inflammation.Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis.Systemic treatments for noninfectious vitreous inflammation.Therapy of ocular Behçet disease.Judicious use of biologicals in juvenile idiopathic arthritis.Adalimumab for treatment of idiopathic frosted branch angiitis: a case reportInvestigational drugs for treatment of juvenile idiopathic arthritis.Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis.Use of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular disease--a case cohort interventional study.Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab.Comparison of the acute effects of anti-TNF-alpha drugs on a uveitis experimental model.Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative
P2860
Q26751204-1749B0F8-9F4C-46C3-9307-20CCE7BE8911Q27025862-DF40DA71-FB16-41F5-8A26-34C18C648B7FQ28069571-F2F9CC08-46D3-4CDF-9771-DCE5F8D286CAQ34070773-3DCCC796-4597-440F-88BF-2A546E966245Q34627012-89C0945D-AD44-44CB-A77B-1A7764033ED0Q34789195-81F72F25-086C-4DE8-B803-A122A735A9B2Q35150941-E98E61F6-66CF-4599-820A-28C7F0DFB60DQ36568645-A17918A7-766E-4420-919C-3ABF2F79A5A2Q36952770-0C2335BF-602C-46F3-847C-E02527872FFCQ37095406-EEF3546F-19F3-47A8-807B-22B917DA73F6Q37105146-780EFDBA-F391-4BA1-9BFA-9B241842FEDCQ37342927-F80E3AD1-5A4E-4AD2-BD6D-3380165D52B1Q37479820-04227487-0ACA-4C63-867B-32B4DE2E7491Q37650221-C9FBF330-7B98-4138-A983-598E06E8C399Q37724245-08E8AB65-3567-4DEE-8FD3-F3C74605365CQ37936394-9B715DF6-1692-4CF1-8BA2-61A3590F7572Q37936459-39BDB879-7976-4BC0-ACFE-2531EF05BE2EQ37956187-C646EAC5-4A0D-4667-814A-56590F68E4F5Q37984565-7B660289-7C19-4716-B478-D6F4DFD9FEECQ38025152-FD8AE83B-AB7A-4931-B012-CB833A07D8CDQ38048774-622EB863-BE54-4765-ACF6-4CD0091D1CA6Q38074446-04B2414A-FDB5-4D52-9F0A-7F9C1D2C8CFBQ38172090-594408CB-9E8F-4832-8852-C1EA47E5A305Q38174652-39084EEA-6925-44A2-B9F3-A96C37414C34Q38248905-8E6ACEA6-F94D-471F-BC2D-7C6E16315D3DQ38308039-FE48033C-36A9-49ED-A2FE-06A25DD05EEBQ38917814-A912E142-4179-4D14-B244-A3E234E0E646Q40139654-1800CD89-DEB8-4055-901D-9429C040281DQ48633069-822212F9-64C3-4D77-AF47-568E01EEC5F6Q50788220-A340DC70-0088-4348-ACB2-5849F508A552Q52600870-94F03FDE-E056-425C-808B-FE6C190E76ADQ57171464-C899188E-0594-47C7-9F8D-A4A87CED28BD
P2860
Biological response modifier therapy for refractory childhood uveitis.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Biological response modifier therapy for refractory childhood uveitis.
@ast
Biological response modifier therapy for refractory childhood uveitis.
@en
type
label
Biological response modifier therapy for refractory childhood uveitis.
@ast
Biological response modifier therapy for refractory childhood uveitis.
@en
prefLabel
Biological response modifier therapy for refractory childhood uveitis.
@ast
Biological response modifier therapy for refractory childhood uveitis.
@en
P2093
P2860
P356
P1476
Biological response modifier therapy for refractory childhood uveitis.
@en
P2093
C Stephen Foster
Karina Quinones
Michael Gallagher
Rene Antonio Cervantes-Castañeda
Taygan Yilmaz
P2860
P304
P356
10.1136/BJO.2007.124081
P407
P577
2007-06-07T00:00:00Z